AMO Pharma

32 articles about AMO Pharma

• AMO Pharma Announces Collaboration with Population Health Research Institute to Advance Proof of Concept Clinical Trial to Assess Efficacy of Tideglusib in Treatment of Arrhythmogenic Cardiomyopathy

  2/15/2024

  AMO Pharma Limited announced a collaboration with Population Health Research Institute, a joint institute of McMaster University and Hamilton Health Sciences in Canada, to advance a clinical proof of concept trial to assess the efficacy of AMO-02, AMO Pharma's investigational oral glycogen synthase kinase 3 beta inhibitor, in the treatment of genotype positive arrhythmogenic cardiomyopathy.

• AMO Pharma Announces Affirming Data from REACH-CDM Clinical Trial for AMO-02 in Treatment of Myotonic Dystrophy

  9/6/2023

  AMO Pharma Limited, a privately held clinical-stage specialty biopharmaceutical company focusing on rare childhood-onset neurogenetic disorders with limited or no treatment options, announced results from the company's REACH-CDM clinical study of the investigational therapy AMO-02 in the treatment of children and adolescents with congenital myotonic dystrophy.

• AMO Pharma Announces Completion of Treatment of Last Patient in Pivotal REACH-CDM Clinical Trial in Myotonic Dystrophy

  4/25/2023

  AMO Pharma Limited announced completion of treatment for the final patient enrolled in the company's REACH-CDM clinical study of the investigational therapy AMO-02.

• AMO Pharma Announces MHRA Confirmation of CDM1-RS as Approvable Primary Outcome Measure in Myotonic Dystrophy

  2/27/2023

  AMO Pharma Limited announced that the UK Medicines and Healthcare products Regulatory Agency has confirmed that the Congenital DM1 Rating Scale can be considered an approvable primary outcome measure in clinical trials to develop a treatment for congenital myotonic dystrophy type 1.

• AMO Pharma Announces Completion of Enrollment in REACH-CDM Study in Congenital Myotonic Dystrophy

  12/6/2022

  AMO Pharma Limited announced completion of patient enrollment in the company's REACH-CDM study of the investigational therapy AMO-02 in treatment of congenital myotonic dystrophy.

• AMO Pharma Announces Additional Private Equity Investment Following Progress in Phase 3 Study in Congenital Myotonic Dystrophy

  5/10/2022

  AMO Pharma Limited announced that current investors have made additional investment in the Company in response to progress in AMO Pharma's potentially pivotal REACH-CDM study, a double-blind, placebo-controlled, randomized clinical trial to assess the efficacy and safety of AMO-02 for the treatment of congenital myotonic dystrophy.

• AMO Pharma Announces Expansion of Pivotal REACH-CDM Study in Congenital Myotonic Dystrophy

  12/22/2021

  AMO Pharma Limited today announced the completion of activation of two additional clinical trial sites in Australia and New Zealand for its pivotal REACH-CDM study evaluating the efficacy and safety of the investigational therapy AMO-02.

• Julia Jones Joins AMO Pharma As Chief Financial Officer And Board Member

  10/14/2021

  AMO Pharma Limited, a privately held biopharmaceutical company focusing on rare, childhood-onset neurogenetic disorders with limited or no treatment options, announced that Julia Jones has joined the company as chief financial officer and a member of the Company's board of directors.

• AMO Pharma Announces First Patient Enrolled In REACH-CDM X 12-Month Open-Label Study

  9/30/2021

   AMO Pharma Limited today announced that the first patient has completed participation in the REACH-CDM pivotal clinical trial and has been enrolled in the REACH-CDM X study

• Accomplished Industry Executive Alan L. Rubino Named Chairman of AMO Pharma Board of Directors

  8/19/2021

  AMO Pharma Limited, a privately held biopharmaceutical company focusing on rare, childhood-onset neurogenetic disorders with limited or no treatment options, announced that Alan L. Rubino has joined the AMO Pharma board of directors as chairman as of August 16, 2021.

• AMO Pharma Awarded Innovation Passport for AMO-02 (Tideglusib) for Treatment of Congenital Myotonic Dystrophy Type 1

  8/17/2021

  AMO Pharma Limited announced that the Company has received innovative licensing and access pathway designation from the UK Medicines and Healthcare products Regulatory Agency for AMO-02, an investigational therapy in development for the treatment of congenital myotonic dystrophy type 1.

• AMO Pharma Announces Activation of Additional Clinical Trial Sites for Pivotal REACH-CDM Study in Congenital Myotonic Dystrophy

  5/17/2021

  AMO Pharma Limited, a privately held biopharmaceutical company focusing on rare, childhood-onset neurogenetic disorders with limited or no treatment options, announced the activation of four additional clinical trial sites in Canada and the United States for its pivotal REACH-CDM study evaluating the efficacy and safety of the investigational therapy AMO-02 in the treatment of congenital myotonic dystrophy.

• AMO Pharma to Participate in Myotonic Dystrophy Foundation Meet the DM Drug Developers Program on March 5, 2021

  3/3/2021

  AMO Pharma Company to present update on REACH-CDM pivotal clinical trial studying use of AMO-02 in treatment of congenital myotonic dystrophy

• 

  Global Roundup: EU Approves ViiV's HIV-1 Drug and More

  12/24/2020

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• FDA Grants Rare Pediatric Disease Designation to AMO Pharma for AMO-02 for Treatment of Congenital Myotonic Dystrophy

  11/9/2020

  AMO Pharma Limited announced that the U.S. Food and Drug Administration has granted a Rare Pediatric Disease designation to AMO-Pharma for AMO-02, the company's investigational therapy in development for the treatment of congenital myotonic dystrophy.

• AMO Pharma to Present at Cowen and Company 40th Annual Health Care Conference

  2/28/2020

  AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare, childhood onset neurogenetic disorders with limited or no treatment options, today announced that its management will present a corporate overview at the Cowen and Company 40 th Annual Health Care Conference at 12 p.m. ET on Tuesday, March 3,

• AMO Pharma Announces Initiation of Planned Pivotal Clinical Trial for Myotonic Dystrophy Following $35m Fund Raise

  1/9/2020

  Trial to assess AMO-02 in treatment of congenital myotonic dystrophy to begin patient enrollment in early 2020.

• AMO Pharma Participates in Workshop on Central Nervous System Involvement in Progression and Treatment of Myotonic Dystrophy During Myotonic Dystrophy Foundation Annual Conference

  9/16/2019

  AMO Pharma Limited ("AMO Pharma"), today announced that Joe Horrigan, MD, AMO Pharma's chief medical officer, presented an update on the company's research targeting use of CNS therapies in the treatment of myotonic dystrophy (DM) during a full-day workshop on CNS involvement in DM held during the Myotonic Dystrophy Foundation Annual Conference

• AMO Pharma Presents Statistical Analysis of Results of Phase 2 Study of AMO-02 in Adolescents with Autism Spectrum Disorder

  5/6/2019

  Results highlighting consistent patterns in efficacy across multiple outcomes measures presented at International Society for Autism Research Annual Meeting in Montreal.

• 

  BioSpace' s Global Biopharma Roundup: April 18

  4/18/2019

  Pharma and biotechs from across the globe share news, pipeline updates, with stories from Vetter, Atomwise, Tessa, GenSight, and more.